LXRX - NASDAQ

Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc.

LXRXยทNASDAQ

$1.94

+2.4%
HealthcareBiotechnology

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$859.52M
EPS-0.1400
P/E Ratio-13.82
Earnings Date07/30/2026
Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc. Fair Value Envelope

LXRX ยท NASDAQ

Our analysis suggests that LXRX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.935, this represents a potential HIDDEN relative to our calculated worth for Lexicon Pharmaceuticals, Inc..

HIDDEN
Intrinsic Value
Current Price: $1.935

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$11.7B
+ Cash & Equivalents$34.3M
Firm Value-$11.7B
- Debt$62.2M
Equity Value-$11.7B
/ Shares Outstanding363,398,860B
DCF Value-$32
OVERVALUED BY 1766%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$110.1M
-$178.7M
-$289.9M
-$470.4M
-$763.3M
-$1.2B
-$2.0B
-$3.3B
-$5.3B
-$8.6B
Maintenance CapEx
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
Owner Earnings
-$110.1M
-$178.7M
-$289.9M
-$470.4M
-$763.3M
-$1.2B
-$2.0B
-$3.3B
-$5.3B
-$8.6B
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$101.9M
-$153.2M
-$230.1M
-$345.8M
-$519.5M
-$780.5M
-$1.2B
-$1.8B
-$2.6B
-$4.0B
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your LXRX research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.